About: Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.46 (-1.27%)
ALGS NASDAQ Aligos Therapeutics Inc
Aligos Therapeutics Inc share price
ALGS price activity
Last Price
$5.460
Change (24hr)
-0.07 USD (-1.27%)
Volume
5.03K
Volume (4w avg)
-
Open
$5.47
Day Range
$5.31 - $5.47
Previous Close
$5.53
Last Trade
13 Oct, 3:40 pm GMT+0
Delayed
13 Oct, 3:40 pm GMT+0
ALGS price performance
Delayed
13 Oct, 3:40 pm GMT+0
ALGS Market Signals